One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...
The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...
Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Bank of America Securities added Booz Allen Hamilton Holding Corp. ( NYSE: BAH) and Datadog Inc. ( DDOG) to its US 1 List, renewing Apple Inc. ( AAPL ), and removing Eli Lilly & Co. ( LLY ).
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.